financetom
Business
financetom
/
Business
/
Tiziana Life Sciences CEO Increases Stake With Share Purchase
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Tiziana Life Sciences CEO Increases Stake With Share Purchase
Mar 10, 2026 10:31 PM

03:33 PM EST, 12/15/2025 (MT Newswires) -- Tiziana Life Sciences ( TLSA ) said Monday its CEO, Ivor Elrifi, purchased 163,400 shares of common stock, bringing his total stake to 357,848 shares.

Shares of the company were down over 17% in recent trading.

Price: 1.47, Change: -0.31, Percent Change: -17.19

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Rackspace Technology Offers to Exchange Senior Secured Notes due 2028
Rackspace Technology Offers to Exchange Senior Secured Notes due 2028
Mar 15, 2024
05:44 AM EDT, 03/15/2024 (MT Newswires) -- Rackspace Technology ( RXT ) said Thursday it is offering eligible holders of its 3.50% first-priority senior secured notes due 2028 to exchange the notes for new 3.50% FLSO senior secured notes due 2028 or partially exchange them for cash. Eligible holders who tender all of their existing secured notes at or before...
Obsidian Energy Completes Offer to Purchase Senior Notes Due 2027
Obsidian Energy Completes Offer to Purchase Senior Notes Due 2027
Mar 15, 2024
05:49 AM EDT, 03/15/2024 (MT Newswires) -- Obsidian Energy ( OBE ) said Thursday it has completed its offer to purchase up to 2 million Canadian dollars ($1.5 million) of its 11.95% senior unsecured notes due July 27, 2027. The company said the offer was oversubscribed, with about CA$49.2 million principal amount of the notes validly tendered by the March...
Gilead CAR-T cancer therapy capacity to quadruple by 2026
Gilead CAR-T cancer therapy capacity to quadruple by 2026
Mar 15, 2024
FREDERICK, Maryland, March 15 (Reuters) - Gilead Sciences ( GILD ) will be able to quadruple production of its cell therapy cancer treatments by 2026 due to improvements in the U.S. biotech's manufacturing processes, an executive in charge of that business told Reuters. Cindy Perettie, executive vice president of Gilead's Kite cell therapy unit, said these changes have already allowed...
Microsoft singles out Google's competitive edge in generative AI
Microsoft singles out Google's competitive edge in generative AI
Mar 15, 2024
(This March 14 story has been corrected to say 15 million euros and not 15 billion euros, in paragraph 11) By Foo Yun Chee BRUSSELS (Reuters) - Alphabet unit Google enjoys a competitive edge in generative artificial intelligence due to its trove of data and AI-optimised chips, Microsoft has told EU antitrust regulators, underscoring the rivalry between the two tech...
Copyright 2023-2026 - www.financetom.com All Rights Reserved